Jump to content

Chupacabra and other migraine sufferers.


SukiSukiNow

Recommended Posts

Thought you might find some hope in this...

 

MAP gets big boost from migraine drug.

 

After reporting a setback with one of its drugs earlier this year, Mountain View-based MAP Pharmaceuticals got a huge boost Tuesday from a study of another drug that appears to hold promise for millions of migraine sufferers.

The company announced that its inhaled migraine treatment, Levadex, met all of the major goals of the late-stage study involving nearly 800 patients with the ailment. The news nearly tripled MAP's stock price, which rose $5.85 to close at $9.

After two hours, patients taking Levadex had significantly less pain, nausea and sensitivity to sound and light, compared with patients taking a placebo, the company said. In addition, MAP said Levadex began relieving pain within 30 minutes and continued to help for up to 48 hours without serious side effects.

That is important, in part because so-called triptans — one widely used class of drugs to treat migraines — can take up to 90 minutes to work and can cause high blood pressure, the company said. In addition, triptans, which usually are given orally, "don't seem to last beyond two to four hours," said Sheena Aurora, a director of the Swedish Headache Center and a paid MAP consultant who worked on the study.

"For the average migraine sufferer, it gives a convenient home therapy which is fast and lasts long," she said.

"Obviously, we're really pleased with this outcome," said MAP CEO Timothy Nelson, adding that MAP plans another study to further evaluate Levadex before asking the U.S. Food and Drug Administration to let it sell the treatment. "We always believed the drug would work this way."

The company's treatment uses dihydroergotamine, an existing drug that is usually injected but also is available as a nasal spray. MAP's formulation uses an inhaler the patient breathes through their mouth. Administering the drug is easier with MAP's product than with the injected form, and MAP's inhaler often gives a more precise dose than is possible with the spray, Nelson said.

In February, MAP suffered a blow when a treatment it is developing for asthma failed to show statistically significant benefit. But Nelson said the company and AstraZeneca, its partner in developing that treatment, are still reviewing data from the study and haven't determined how to proceed.

In a note to its clients, investment bank Leerink Swann said if Levadex is approved for sale to migraine suffers, it could generate up to $270 million a year worldwide. The note added that other companies might be interested in buying an interest in Levadex, a possibility Nelson said he would consider.

Nearly 30 million Americans endure migraines, according to the National Headache Foundation. Women are three times more likely than men to have the ailment, which typically affects people 15 to 55. Migraines can be triggered by a variety of factors, including a missed meal, medications that swell blood vessels, bright lights, noise, watching television and some types of food.

Link to comment
Share on other sites

This forum is supported by the 12ozProphet Shop, so go buy a shirt and help support!
This forum is brought to you by the 12ozProphet Shop.
This forum is brought to you by the 12oz Shop.

Awesome. Unfortunately, i don't have migraines per say, but chronic headaches. I don't get any of the other migraine effects like naseau, sensitivity to bright lights, and auras, i just have miserable headaches half of my waking life and less miserable headaches the other half. I'll still definitely read more about it though.

Link to comment
Share on other sites

Join the conversation

You can post now and register later. If you have an account, sign in now to post with your account.

Guest
Reply to this topic...

×   Pasted as rich text.   Paste as plain text instead

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

×
×
  • Create New...